Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ACADIA Pharmaceuticals Inc. - Common Stock (NQ:ACAD)

26.09 +0.10 (+0.38%)
Streaming Delayed Price Updated: 10:28 AM EST, Jan 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 155,643
Open 25.72
Bid (Size) 26.12 (100)
Ask (Size) 26.17 (100)
Prev. Close 25.99
Today's Range 25.25 - 26.10
52wk Range 13.40 - 28.35
Shares Outstanding 162,625,379
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) Shows Strong Growth Momentum and Technical Setup ↗
Via Chartmill
News headline image
Acadia Pharmaceuticals Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference
From Acadia Pharmaceuticals Inc.
Via Business Wire

Performance

YTD
-0.8%
-0.8%
1 Month
-7.0%
-7.0%
3 Month
+24.6%
+24.6%
6 Month
+17.1%
+17.1%
1 Year
+45.8%
+45.8%

More News

Read More
News headline image
Rhythm Pharmaceuticals Faces Gravity: FDA Delays and Valuation Pressures Cool 2025’s Biotech Darling
Via MarketMinute
Topics ETFs Economy World Trade
News headline image
ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) Shows Strong Growth Momentum and Technical Setup for Breakout ↗
Via Chartmill
News headline image
Earnings Scheduled For November 5, 2025 ↗
Via Benzinga
News headline image
Acadia Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Acadia Pharmaceuticals Announces FDA Approval of DAYBUE® STIX (trofinetide) for Oral Solution, a New Powder Formulation of Trofinetide for the Treatment of Rett Syndrome
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Acadia Stock Up 59% in a Year — Is a $51 Million New Stake a Bet on a Bigger Rebound? ↗
Via The Motley Fool
News headline image
Healthcare Investor Exits $13 Million Stake STAAR Surgical Stake as Alcon Deal Drama Looms ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
PTC Therapeutics Swings to a Profit on $211 Million in Revenue — Is This Why a Major Fund Just Invested $32 Million? ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Dyne Therapeutics Stock Down 30% in a Year — So Why Did One Investor Add Nearly 1 Million Shares? ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) Shows Strong Growth Momentum and Technical Setup ↗
Via Chartmill
News headline image
Why Dyne Therapeutics Stock Was Crushing it This Week ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Acadia Pharmaceuticals to Participate in Citi’s 2025 Global Healthcare Conference
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Beyond The Numbers: 6 Analysts Discuss ACADIA Pharmaceuticals Stock ↗
Via Benzinga
News headline image
Acadia (ACAD) Q3 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Acadia Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operating Overview
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
ACADIA Pharmaceuticals's Earnings: A Preview ↗
Via Benzinga
News headline image
ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) Presents a Compelling Growth and Breakout Profile ↗
Via Chartmill
News headline image
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Halper Sadeh LLC Encourages Acadia Pharmaceuticals Inc. Shareholders to Contact the Firm to Discuss Their Rights
From Halper Sadeh LLC
Via Business Wire
News headline image
This ACADIA Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday ↗
Via Benzinga
News headline image
ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) Fits the 'Affordable Growth' Investment Framework ↗
Via Chartmill
News headline image
Acadia Pharmaceuticals to Announce Third Quarter 2025 Financial Results on November 5, 2025
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) Shows Strong Growth and Positive Technical Setup ↗
Via Chartmill

Frequently Asked Questions

Is ACADIA Pharmaceuticals Inc. - Common Stock publicly traded?
Yes, ACADIA Pharmaceuticals Inc. - Common Stock is publicly traded.
What exchange does ACADIA Pharmaceuticals Inc. - Common Stock trade on?
ACADIA Pharmaceuticals Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for ACADIA Pharmaceuticals Inc. - Common Stock?
The ticker symbol for ACADIA Pharmaceuticals Inc. - Common Stock is ACAD on the Nasdaq Stock Market
What is the current price of ACADIA Pharmaceuticals Inc. - Common Stock?
The current price of ACADIA Pharmaceuticals Inc. - Common Stock is 26.09
When was ACADIA Pharmaceuticals Inc. - Common Stock last traded?
The last trade of ACADIA Pharmaceuticals Inc. - Common Stock was at 01/20/26 10:28 AM ET
What is the market capitalization of ACADIA Pharmaceuticals Inc. - Common Stock?
The market capitalization of ACADIA Pharmaceuticals Inc. - Common Stock is 4.24B
How many shares of ACADIA Pharmaceuticals Inc. - Common Stock are outstanding?
ACADIA Pharmaceuticals Inc. - Common Stock has 4B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.